Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1824875 | 0.82 | MAOA (0.48) | TAAR1TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL12170820 | 0.81 | WDR5 (0.41) | ALDH1A1 | |
| SCHEMBL2850237 | 0.80 | KCNA3 (0.43) | TAAR1TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL12170819 | 0.79 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL4205437 | 0.78 | TAAR1 (0.42) | TAAR1TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL3048952 | 0.77 | ACACB (0.44) | TAAR1TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL9080688 | 0.74 | TDP1 (0.38) | TAAR1TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL36030 | 0.74 | MEN1 (0.41) | TDP1KCNA3CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL1714455 | 0.74 | ALDH1A1 (0.42) | TDP1KCNA3ALDH1A1RECQL | |
| SCHEMBL3512638 | 0.74 | PARP10 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4429872-A1 | VAT POLYMERIZATION PROCESS | Polyfos 3D Ltd (IL) | 2024-09-18 | — | — | EP | claimed |
| WO-2023084517-A1 | VAT POLYMERIZATION PROCESS | POLYFOS 3D LTD (IL) | 2023-05-19 | — | — | WO | claimed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | claimed |
| US-20250010542-A1 | VAT POLYMERIZATION PROCESS | POLYFOS 3D LTD (IL) | 2025-01-09 | — | — | US | disclosed |
| EP-4429872-A1 | VAT POLYMERIZATION PROCESS | Polyfos 3D Ltd (IL) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023084517-A1 | VAT POLYMERIZATION PROCESS | POLYFOS 3D LTD (IL) | 2023-05-19 | — | — | WO | disclosed |
| US-11498268-B2 | Method of making 3D printed objects by dispensing sequential layers of material | PHOTOCENTRIC LIMITED (GB) | 2022-11-15 | — | — | US | disclosed |
| US-11491711-B2 | Method of making 3D printed objects using two distinct light sources | PHOTOCENTRIC LIMITED (GB) | 2022-11-08 | — | — | US | disclosed |
| US-20200282637-A1 | METHOD OF MAKING 3D PRINTED OBJECTS BY DISPENSING SEQUENTIAL LAYERS OF MATERIAL | PHOTOCENTRIC LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-20200282638-A1 | METHOD OF MAKING 3D PRINTED OBJECTS USING TWO DISTINCT LIGHT SOURCES | PHOTOCENTRIC LIMITED (GB) | 2020-09-10 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | TAAR1 4501/4885TDP1 2767/4885KCNA3 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.